glp 1 china ๐๐งฌChina has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyidaยฎ) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese
Pay in 4 interest-free payments of $5.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 31 - Sep 5
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](https://resource.chemlinked.com.cn/baipharm/articles/chinas-glp-1-ra-market-is-fueled-by-glycemic-control-weight-loss-needs.jpg)
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](https://thechinaproject.com/wp-content/uploads/2023/07/2014-03-03T160131Z_440591494_MT1PRA19191605_RTRMADP_3_PA-IMAGES-scaled.jpg)
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](http://www.csbiochina.com/attachments/image/20260129/20260129150242_6771.png)
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](https://earthtimes.org/wp-content/uploads/2026/03/China-Opens-Its-Weight-Loss-Drug-Market-to-Pfizers-GLP-1-Therapy-300x200.png)
![glp 1 china China has approved the world's first cAMP-biased GLP-1 receptor agonist for type 2 diabetes, developed by Hangzhou-based Sciwind Biosciences. Approved on Jan. 30, Ennoglutide Injection (Xianyida) is the first Class innovative Updated] GLP-1-RAs Swoop to Chinese](https://assets.ups.com/adobe/assets/urn:aaid:aem:6f41691d-4aee-424f-bec7-5072c3156383/as/glp-1-image-1.avif?assetname=glp-1-image-1.png)



















